Accredited Continuing Education
Accreditation Statement
The Society for Cardiovascular Angiography and Interventions (SCAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Interventional Cardiology Program Credit Designation
SCAI designates this live activity for a maximum of 14.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Congenital Heart Disease Program Credit Designation
SCAI designates this live activity for a maximum of 12 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 14.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
ABP MOC
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 12 medical knowledge MOC points in the American Board of Pediatric’s (ABP) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.
Nurses and Radiologic Technicians
Nurses and Radiology Technologists: This education activity is pending approval by the Cardiovascular & Pulmonary Continuing Education (CaPCE) for up to 14.5 contact hours of accredited education. Provider approved by the California Board of Registered Nursing, Provider Number CEP1531.
Successful Completion
Check into the conference onsite and pick up your badge. This creates an attendance record. Participate in the program. Then, complete the post-activity evaluation to claim credit.
SCAI-Sponsored Satellite Symposia Programming
In addition to the Scientific Sessions program described above, SCAI offers CME satellite symposia opportunities. These symposia represent a possible additional 18.5 AMA PRA Category 1 CreditsTM. CE information for the satellite symposia can be found in the Conference Program.
Disclosures
Individuals in control of content disclosed the following relevant relationships with ineligible companies during the content development process for this activity.
Program Committee/Planners
Program Chairs
- Binita Shah: Philips, advisory board and Terumo Medical, consulting.
- Sahil Parikh: Abbott, Shockwave Medical, TriReme Medical, Surmodics, and Silk Road Medical; has received consulting fees from Terumo and Abiomed; and has served on the Advisory Boards of Abbott, Medtronic, and Boston Scientific.
- Andrew Klein: No financial relationships with ineligible companies.
Congenital Heart Disease Program
- Zahid Amin: Abbott, consulting, speaker and Edwards Lifesciences, consulting.
- Howaida El-Said: No financial relationships with ineligible companies.
- Athar M. Qureshi: Medtronic, consulting; W.L. Gore and Associates, Inc., consulting and B. Braun, consulting.
Coronary Track
- Manish A. Parikh: Abbott, Boston Scientific, and Medtronic, advisory board.
- Margaret McEntegart: Asahi Intecc, honorarium; Boston Scientific, speaker; ShockWave Medical, Inc., consulting, speaker; and Teleflex, consulting.
- Rajan A. Patel: Abiomed - Advisory Board/Board Member, PI, Speaker. Boston Scientific Corp. - Speaker Bureau. LivaNova - Speaker Bureau.
- Evan Shlofmitz: Amgen, Janssen Pharmaceuticals, and Novo Nordisk, speaker; and Abbott, ACIST Medical, Boston Scientific, Chiesi, Philips, Shockwave Medical, Terumo and Xenter, consulting.
Interventional Leadership Track
- Lyndon C. Box, Guarav Tyagi, and Tara L. Jones: No financial relationships with ineligible companies.
- Amit N. Vora: Medtronic, consulting.
Peripheral Track
- Jon C. George: Abbott , consulting; Abiomed, consulting. Boston Scientific Corp. and Medtronic, consulting.
- Sonal Pruthi and J. Antonio Gutierrez: No financial relationships with ineligible companies.
- Jun Li: Abbott - Advisory Board/Board Member, Principal Investigator for a Research Study. Medtronic - Consulting. Boston Scientific Corp. - Consulting. Inari – Consulting
Structural Track
- Azeem Latib and Ranya Sweis: No financial relationships with ineligible companies.
- Triston B.B.J. Smith: Edwards Lifesciences, consulting; Zoll, speaker.
- Molly Szerlip: Boston Scientific Corp., speaker. Abbott, advisory board; Edwards Lifesciences, consulting.
Staff: Robert Bartel and Rachel Pham have no financial relationships with ineligible companies.
Faculty disclosures can be found in the Conference App under the faculty listing.
Independent Content
As a provider of continuing medical education through the Accreditation Council for Continuing Medical Education (ACCME), it is the Society’s policy to ensure balance, independence, objectivity, and scientific rigor in all its activities.
Planning Process
The SCAI 2024 Scientific Sessions were developed by the SCAI planners prior to and independent of commercial support. Members of the Program Committee reviewed and approved this activity. If planners had relevant financial relationships, the agenda was peer reviewed by a member with no relevant financial relationships.
Mitigation of Relevant Financial Relationships
All participating planners, reviewers, faculty, and staff are required to disclose to SCAI all financial relationships with ineligible companies. SCAI identifies relevant financial relationships and mitigates them before the activity begins.
Content Validation Statement
SCAI accepts the following Content Validation Statements and expects all persons involved in its professional education activities to abide by these statements for clinical care recommendations.
All clinical and pharmacological recommendations are based on evidence accepted within the medical profession as adequate jurisdiction for their indications and contradictions in patient care. SCAI does not promote recommendations, treatment, or manners of practicing medicine that are not within the definition of accredited continuing education or known to have risks or dangers that outweigh the benefits or known to be ineffective in the treatment of patients.
All research referenced to support or justify patient care recommendations conforms to accepted standards of experimental design, data collection and analysis.
SCAI actively promotes improvements in health care and NOT proprietary interests of an ineligible company. SCAI's educational content is free of marketing or sales of products or services.
Faculty will not actively promote or sell products or services that serve their professional or financial interests during accredited education.
SCAI encourages faculty to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration (FDA), at first mention and where appropriate in the content.